AB1033
Anti-Versican Antibody, a.a. 1360-1439 of mouse versican
Chemicon®, from rabbit
Synonym(s):
GAG beta Domain
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
rabbit
Quality Level
antibody form
affinity purified immunoglobulin
antibody product type
primary antibodies
clone
polyclonal
species reactivity
mouse
manufacturer/tradename
Chemicon®
technique(s)
immunohistochemistry: suitable (paraffin)
immunoprecipitation (IP): suitable
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
dry ice
target post-translational modification
unmodified
Gene Information
human ... ACAN(176)
General description
Versican is a large multi-domain chondroitin sulphate proteoglycan, is secreted by fibroblasts and other types of cells. It has a N-terminal hyaluronic acid (HA) binding domain. This domain has homology with the G1 and G2 domains of aggrecan, (G1 is the hyaluronic acid binding region), to cartilage link protein which stabilizes the binding of aggrecan to hyaluronic acid, and, to the hyaluronate receptor CD44. In addition, versican also has a lectin like domain, a C-terminal compliment repeat, and two EGF-like repeats, all of which can be found in aggrecan., Versican has an apparent molecular mass of ca. 1000 kDa, of which the core contributes 400 kDa from the 2409 amino acids, and the 12 -15 covalently attached chondroitin sulphate chains make up the rest.
Specificity
Mouse versican GAG beta domain.
Immunogen
Epitope: a.a. 1360-1439 of mouse versican
GST fusion protein containing amino acids 1360-1439 of mouse versican.
Application
Anti-Versican Antibody, a.a. 1360-1439 of mouse versican is an antibody against Versican for use in IP, WB, IH(P).
Immunohistochemistry (formally fixed, paraffin embedded): 10 μg/mL. Tissues must be treated with Chondroitinase before staining. {0.5U/mL in 100mM Tris-HCL pH 7.2-7.4, 30 minutes at room temperature} Then block and stain.
Western blotting: 0.5 μg/mL
Immunoprecipitation:
Optimal working dilutions must be determined by the end user.
Western blotting: 0.5 μg/mL
Immunoprecipitation:
Optimal working dilutions must be determined by the end user.
Physical form
Format: Purified
The immunoglobulin was affinity purified against the recombinant antigen and is presented in PBS. Anti-GST reactivity has not been adsorbed. Liquid in PBS.
Storage and Stability
Maintain at -20°C in undiluted aliquots for up to 6 months after date of receipt. Avoid repeat freeze/thaw cycles.
Analysis Note
Control
Immunohistochemistry Positive control: surrounding cartilageWestern blotting positive control: total 13 day mouse embryo
Immunohistochemistry Positive control: surrounding cartilageWestern blotting positive control: total 13 day mouse embryo
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Not finding the right product?
Try our Product Selector Tool.
Storage Class
12 - Non Combustible Liquids
wgk_germany
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Design of a miniature tissue culture system to culture mouse heart valves.
Lieber SC, Kruithof BP, Aubry N, Vatner SF, Gaussin V
Annals of Biomedical Engineering null
Proteolytic cleavage of versican and involvement of ADAMTS-1 in VEGF-A/VPF-induced pathological angiogenesis.
Fu, Y; Nagy, JA; Brown, LF; Shih, SC; Johnson, PY; Chan, CK; Dvorak, HF; Wight, TN
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society null
Fabienne Meier-Abt et al.
Breast cancer research : BCR, 15(2), R36-R36 (2013-04-30)
Early pregnancy has a strong protective effect against breast cancer in humans and rodents, but the underlying mechanism is unknown. Because breast cancers are thought to arise from specific cell subpopulations of mammary epithelia, we studied the effect of parity
Angiotensin II increases vascular proteoglycan content preceding and contributing to atherosclerosis development.
Huang, F; Thompson, JC; Wilson, PG; Aung, HH; Rutledge, JC; Tannock, LR
Journal of Lipid Research null
Early but not late pregnancy induces lifelong reductions in the proportion of mammary progesterone sensing cells and epithelial Wnt signaling.
Meier-Abt, F; Brinkhaus, H; Bentires-Alj, M
Breast Cancer Research null
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service